接受exagamglogene autotemcel治疗的输血依赖型β地中海贫血患者健康相关生活质量改善
本研究在54例接受exa-cel输注且随访≥16个月的输血依赖型β地中海贫血患者中观察患者报告结局变化,成人35例、青少年19例。成人EQ-5D-5L三种评分及FACT-BMT相关评分至第48个月均改善并超过最小临床重要差异;青少年第24个月EQ-5D-Y视觉模拟评分和PedsQL总分较基线升高。
要点
- 成人exa-cel输注后EQ-5D-5L视觉模拟评分及美国、英国健康效用指数评分均改善,第48个月超过最小临床重要差异。
- 成人FACT-G总分及骨髓移植分量表评分至第48个月改善并超过最小临床重要差异,4个FACT-G分量表均改善。
- 青少年第24个月EQ-5D-Y视觉模拟评分和PedsQL总分较基线升高,躯体与心理社会健康子成分持续改善。
核心结论
- exa-cel可使成人和青少年输血依赖型β地中海贫血患者获得广泛、持久且具有临床意义的健康相关生活质量改善。
研究设计与样本
- 一项3期临床试验中54例接受exa-cel输注的输血依赖型β地中海贫血患者,成人35例、青少年19例,随访≥16个月。
主要发现
- 成人基线平均EQ-5D-5L视觉模拟评分及美国、英国健康效用指数评分与已报道的输血依赖型β地中海贫血成人基线评分一致。
- 成人exa-cel输注后上述3种评分均改善,第48个月超过既定的最小临床重要差异。
- 成人平均FACT-G评分和骨髓移植分量表评分至第48个月改善并超过最小临床重要差异,FACT-G的躯体、社会/家庭、情感和功能健康4个分量表均改善。
- 青少年第24个月平均EQ-5D-Y视觉模拟评分和PedsQL总分较基线升高,躯体与心理社会健康子成分均持续改善。
关键数值与推荐
- 成人评估工具为EQ-5D-5L和FACT-BMT。
- 青少年评估工具为EQ-5D-Y和PedsQL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transfusion-dependent β-thalassemia (TDT) can have negative impacts on a patient's health-related quality of life (HRQoL). Exagamglogene autotemcel (exa-cel) is a one-time, ex vivo CRISPR-Cas9 gene-edited cell therapy for TDT shown in a phase 3 clinical trial to result in transfusion independence in most participants. Here, we describe changes in patient-reported outcome (PRO) measures after exa-cel infusion in 54 participants (adults, n = 35; adolescents, n = 19), who had ≥16 months of follow-up. In adults, PRO measures included the EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) and the Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT). In adolescents, the EuroQol Quality of Life Scale-5 dimensions-youth (EQ-5D-Y) and Pediatric Quality of Life Inventory (PedsQL) instruments were used. At baseline, mean EQ-5D-5L visual analog scale (VAS) and US and UK health utility index scores in adults were in line with baseline scores reported for adults with TDT. After exa-cel infusion, all 3 scores improved, exceeding established minimal clinically important differences (MCIDs) at month 48. Mean FACT-General (FACT-G) score and bone marrow transplant subscale score improved through month 48, also exceeding MCIDs, with improvements in all 4 FACT-G subscales (physical, social/family, emotional, and functional well-being). Consistent with HRQoL improvements in adults, adolescents had increases from baseline at month 24 in mean EQ-5D-Y VAS score and PedsQL total score, with sustained improvements in both physical and psychosocial health subcomponents. These results indicate exa-cel leads to broad, durable, and clinically meaningful improvements in HRQoL in adults and adolescents with TDT. These trials were registered at www.ClinicalTrials.gov as #NCT03655678 and #NCT04208529.
引用
- Fuente J, Frangoul H, Lang P, et al. Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel. Blood Adv. 2025. PMID: 40862696. doi:10.1182/bloodadvances.2025016702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。